ClinicalTrials.gg
RecruitingNCT05960955Updated Nov 18, 2023

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of Cadonilimab and AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

02

Conditions studied

  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be able and willing to provide written .
  • 18 to 75 years old.
  • Has an (ECOG) performance status of 0 or 1.
  • Has a confirmed diagnosis of Gastric or Gastroesophageal Junction Adenocarcinoma(G/GEJ).
  • Has Stage T3-4N+M0 G/GEJ (American Joint Committee on Cancer [AJCC])
  • Has based on (RECIST) 1.1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Are there suspected or locally advanced, unresectable disease, regardless of disease stage.
  • Is currently participating in a study of an agent or using an investigational device.
  • Has undergone major surgery within 30 days of Study Day 1.
  • Has an active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, or drugs).
  • Has known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected).
  • History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  • Has received a within 30 days of the planned first dose of study therapy.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Part 1 cohort 1

    Subjects receive cadonilimab combination chemotherapy(SOX) neoadjuvant therapy 3 cycles.

    Drug: Cadonilimab · Drug: Oxaliplatin · Drug: Tegafur-gimeracil-oteracil potassium

  • Experimental
    Part 1 cohort 2

    Subjects receive cadonilimab combination chemotherapy(SOX) and AK117 neoadjuvant therapy 3 cycles.

    Drug: Cadonilimab · Drug: AK117 · Drug: Oxaliplatin · Drug: Tegafur-gimeracil-oteracil potassium

  • Experimental
    Part 2 cohort 1

    Subjects receive cadonilimab combination chemotherapy(FLOT) neoadjuvant therapy 4 cycles.

    Drug: Cadonilimab · Drug: Oxaliplatin · Drug: Docetaxel · Drug: 5-Fluorouracil

  • Experimental
    Part 2 cohort 2

    Subjects receive cadonilimab combination chemotherapy(FLOT) and AK117 neoadjuvant therapy 4 cycles.

    Drug: Cadonilimab · Drug: AK117 · Drug: Oxaliplatin · Drug: Docetaxel · Drug: 5-Fluorouracil

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE), rate of surgical delays, abnormal laboratory findings of clinical significance

    Time frame: Up to approximately 2 years

  2. Pathological complete response (pCR) rates

    pCR is defined the 0% residual viable tumor cells in the primary tumor and sampled lymph nodes

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Major pathological response(MPR) rates

    MPR is defined the ≤10% residual viable tumor cells in the primary tumor and sampled lymph nodes

    Time frame: Up to approximately 2 years

  2. Tumor regression grade(TRG)

    Time frame: Up to approximately 2 years

  3. R0 resection rate

    Time frame: Up to approximately 2 years

  4. Tumor descending stage rate

    Proportion of subjects whose tumor TNM stage decreased from baseline before surgery

    Time frame: Up to approximately 2 years

  5. ORR

    Time frame: Up to approximately 2 years

  6. EFS

    Time frame: Up to approximately 2 years

  7. OS

    Time frame: Up to approximately 2 years

  8. PK

    Serum drug concentrations of cadonilimab and/or AK117 in individual subjects at different time points

    Time frame: Up to approximately 2 years

  9. ADA

    Number of subjects with detectable anti-drug antibodies (ADA).

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Nov 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Jul 27, 2023
StartActual
Nov 13, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Nov 30, 2027
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05960955
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Nov 13, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 18, 2023

Study contacts

Weifeng Song, MD
Contact
clinicaltrials@akesobio.com
+86(0760)89873999
Han Liang, MD
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ligufalimab

Start the discussion